XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
D
D

DaVita

Nieuws

Reuters - 1 dag geleden

U.S. STOCKS Primerica, Affirm Holdings, 3D Systems

BUZZ-U.S. STOCKS ON THE MOVE-Primerica, Affirm Holdings, 3D Systems Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 inched up in choppy trading on Friday ahead of a long weekend, after signs of moderating price pressures, strengthened bets for an interest-rate cut at the U.S.
A
G
I
N
U
U
U
D
D
Reuters - 1 week geleden

Nuwellis and Davita Mutually Agree To Terminate Supply And Collaboration Agreement

BRIEF-Nuwellis and Davita Mutually Agree To Terminate Supply And Collaboration Agreement Aug 22 (Reuters) - DaVita Inc DVA.N : NUWELLIS - CO, DAVITA INC MUTUALLY AGREED TO TERMINATE ITS SUPPLY AND COLLABORATION AGREEMENT, DATED AS OF JUNE 19, 2023 Source text for Eikon: [ID:n0001140361-24-038108] Further company coverage: DVA.N
D
Reuters - 2 weken geleden

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises
A
A
B
D
P
P
V
A
D
T
A
E
F
G
Z
B
D
Reuters - 4 weken geleden

DaVita Inc reports results for the quarter ended in June - Earnings Summary

DaVita Inc reports results for the quarter ended in June - Earnings Summary DaVita Inc DVA.N reported quarterly adjusted earnings of $2.50​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.91. The mean expectation of six analysts for the quarter was for earnings of $2.54 per share.
D
Reuters - 4 weken geleden

DaVita lifts annual profit forecast on strong kidney dialysis services demand

DaVita lifts annual profit forecast on strong kidney dialysis services demand Aug 6 (Reuters) - Healthcare company DaVita DVA.N raised its 2024 profit forecast on Tuesday expecting strong demand for its kidney dialysis services, sending shares of the company up 3% in aftermarket trade. Shares of DaVita, similar to those of its peers, witnessed a steep fall in October last year and gradually recovered in 2024, after the company downplayed speculations over the impact of new GLP-1 weight-loss drug
D
Reuters - 4 weken geleden

DaVita Q2 EPS USD 2.5

BRIEF-DaVita Q2 EPS USD 2.5 Aug 06 (Reuters) - DaVita Q2 operating income USD 506 million. Q2 operating cash flow USD 799 million Q2 free cash flow USD 654 million Q2 adjusted EPS USD 2.59 vs. IBES estimate USD 2.54
D
Reuters - 4 weken geleden

Rollercoaster markets, Nikkei rebounds 10%

MORNING BID AMERICAS-Rollercoaster markets, Nikkei rebounds 10% A look at the day ahead in U.S. and global markets from Mike Dolan The speed and scale of Tuesday's 10% Tokyo bounce after its worst day in 37 years suggests the wild global market swings of the past week are more rooted in speculative churn than economic fright. While that's only partly reassuring - as persistent market turbulence can itself sap economic activity - there's good reason to believe a slowing U.S.
A
C
N
U
W
J
U
U
U
F
F
D
I
J
M
S
B
Reuters - 4 weken geleden

DaVita Inc <DVA.N> expected to post earnings of $2.54 a share - Earnings Preview

DaVita Inc expected to post earnings of $2.54 a share - Earnings Preview DaVita Inc DVA.N , DVA is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2024 The Denver Colorado-based company is expected to report a 5.1% increase in revenue to $3.152 billion from $3 billion a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
D
Reuters - 1 maand geleden

DaVita falls on reaching agreement with US DOJ to resolve illegal kickback allegations

BUZZ-DaVita falls on reaching agreement with US DOJ to resolve illegal kickback allegations ** Shares of healthcare company DaVita DVA.N fall 2.8% to $135.93 in afternoon trade ** Co mpany says it has agreed to pay over $34 mln to the U.S. Department of Justice (DOJ) for resolving allegations of paying illegal kickbacks to nephrologists and vascular access physicians to induce referral of patients to its dialysis centers ** DOJ alleges DaVita paid "improper remuneration" to a large nephrology pr
F
D
Reuters - 1 maand geleden

U.S. Justice Department Says Davita To Pay Over $34 Million To Resolve Allegations Of Illegal Kickbacks

BRIEF-U.S. Justice Department Says Davita To Pay Over $34 Million To Resolve Allegations Of Illegal Kickbacks July 18 (Reuters) - DaVita Inc DVA.N : U.S. JUSTICE DEPARTMENT SAYS DAVITA TO PAY OVER $34 MILLION TO RESOLVE ALLEGATIONS OF ILLEGAL KICKBACKS Source text for Eikon: [ID:] Further company coverage: DVA.N (Reporting By Eric Beech)
D
Reuters - 2 maanden geleden

U.S. STOCKS Morgan Stanley, Datadog, Berkshire Hathaway

BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Datadog, Berkshire Hathaway Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street jumped in upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided market sentiment.
A
A
C
G
T
U
U
D
Reuters - 2 maanden geleden

DaVita falls on report of FTC launching an investigation into co

BUZZ-DaVita falls on report of FTC launching an investigation into co ** Shares of dialysis firm DaVita DVA.N fall 2.8% to $137.59 ** The U.S. Federal Trade Commission is investigating DVA and Fresenius Medical Carev FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday ** The F
F
D
Reuters - 2 maanden geleden

US FTC probing DaVita, Fresenius Medical, Politico reports

UPDATE 1-US FTC probing DaVita, Fresenius Medical, Politico reports Adds more details in paragraph 4, background in paragraph 6 July 13 (Reuters) - The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
F
D
Reuters - 2 maanden geleden

US Federal Trade Commission Is Investigating Dialysis Providers Davita And Fresenius Medical Care- Politico

BRIEF-US Federal Trade Commission Is Investigating Dialysis Providers Davita And Fresenius Medical Care- Politico July 13 (Reuters) - US FEDERAL TRADE COMMISSION IS INVESTIGATING DIALYSIS PROVIDERS DAVITA AND FRESENIUS MEDICAL CARE- POLITICO Source https://tinyurl.com/ym3t3yby
F
D
Reuters - 2 maanden geleden

US FTC probing DaVita, Fresenius Medical, Politico reports

US FTC probing DaVita, Fresenius Medical, Politico reports July 13 (Reuters) - The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
F
D
Reuters - 3 maanden geleden

Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase

BRIEF-Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase June 6 (Reuters) - DaVita Inc DVA.N : NUWELLIS AND DAVITA EXTEND SUPPLY AND COLLABORATION AGREEMENT PILOT PHASE NUWELLIS INC - EXTENSION OF ITS PILOT PHASE UNDER SUPPLY AND COLLABORATION AGREEMENT WITH DAVITA INC. UNTIL AUGUST 31 Source text for Eikon: ID:nGNXt5rsk Furt
D

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.